Skip to content

Safety and Efficacy of Mirazid for Schistosomiasis Treatment

Safety and Efficacy of Mirazid for Schistosomiasis Treatment as Compared to Praziquantel: An Open-label Randomized Non-placebo-Controlled Study

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01529710
Acronym
PHAR0211
Enrollment
200
Registered
2012-02-09
Start date
2011-12-31
Completion date
2012-09-30
Last updated
2015-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schistosoma Hematobium Infection, Schistosomiasis Mansoni

Keywords

Schistosomiasis hematobium, Schistosomiasis mansoni

Brief summary

Clinical Trial Phase:Phase III Primary Objectives: * Compare Mirazid and Praziquantel cure rates for both Schistosoma species. * Compare Mirazid and Praziquantel effect in lowering the intensity of infection for both Schistosoma species. Secondary Objective:Identify and compare the types and severity of side and adverse effects between the Mirazid and Praziquantel. Study Population:200 Schistosomiasis infected persons of both types of Schistosomiasis aged from 15-35 years. Those subjects will be selected from among those screened.Subjects will include both genders excluding chronically ill such as chronic liver disease patients and those with both types of Schistosomiasis. Recruitment Period:3 months and subjects follow up for another 3 months followed by 3 months for statistical analysis and report writing Study Duration: Total study duration is expected to be 9 months: 3 months for recruitment, 3 months for follow up and 3 months for data management and report writing. Endpoints: Will be measured at 3 months of successful administration of treatment either Mirazid or Praziquantel as per the randomization scheme. By then, final assessment of the response to treatment will be done by examining urine or stool of the subject for presence of Schistosoma eggs and its density if found. Three negative urine or stool samples collected 2-days apart at 12 weeks post treatment will indicate treatment success. One positive sample collected at week 12 will indicate infection with Schistosomiasis.

Detailed description

Study Design:This is a phase III, open-label randomized non-placebo-controlled Study in which the investigators will compare the efficacy and safety of Mirazid to Praziquantel as a treatment for Schistosomiasis. After screening, positive subjects for one of the Schistosomiasis will be recruited in the study. They will be treated by Mirazid as 600 mg oral (Soft Gelatin Capsules) for 6 consecutive days or 40mg/Kg body weight of Praziquantel as a single oral dose. Subjects will be evaluated for success of treatment at 12 weeks of treatment. Evaluation will be done by examining urine or stool samples for Schistosomiasis including egg counts for the positive cases.

Interventions

DRUGMyrrh

Subjects will be treated by Mirazid as 600 mg oral (Soft Gelatin Capsules) for 6 consecutive days or 40mg/Kg body weight of Praziquantel as a single oral dose. Subjects will be evaluated for success of treatment at 12 weeks of treatment. Evaluation will be done by examining urine or stool samples for Schistosomiasis including egg counts for the positive cases.

Sponsors

Pharco Pharmaceuticals
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
15 Years to 30 Years
Healthy volunteers
No

Inclusion criteria

* Adolescent and young adults aged 15-30 years * Positive for Schistosoma infection of any type.

Exclusion criteria

* Mixed Schistosoma infection of both types * History of administration of treatment for Schistosoma infection in the last 6 months prior to the study. * Severely ill patients * Advanced chronic liver disease.

Design outcomes

Primary

MeasureTime frame
Compare Mirazid and Praziquantel cure rates for both Schistosoma species, and effect in lowering the intensity of infection for both Schistosoma species.9 months

Secondary

MeasureTime frame
Identify and compare the types and severity of side and adverse effects between the Mirazid and Praziquantel.9 months

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026